Form 4: Castle Biosciences CFO Exercises RSUs, Sells Shares for Tax

Castle Biosciences Chief Financial Officer Frank Stokes acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.

Summary

• Frank Stokes, Chief Financial Officer of Castle Biosciences Inc. (CSTL), reported transactions involving the company's common stock.
• On December 9, 2025, Stokes acquired 14,616 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 6,534 shares were disposed of at a price of $38.25 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions on December 9, 2025, Stokes beneficially owned 51,410 shares of common stock.
• On December 10, 2025, Stokes acquired an additional 6,170 shares of common stock from another RSU vesting event.
• Subsequently, 2,758 shares were disposed of at a price of $38.02 per share to cover tax withholding for this vesting.
• After all reported transactions, Stokes' beneficial ownership stands at 54,822 shares of common stock.
• The RSUs vested on December 9, 2025, were part of a grant of 58,467 RSUs from December 9, 2022, which vest in four equal installments.
• The RSUs vested on December 10, 2025, were part of a grant of 24,679 RSUs from December 10, 2021, also vesting in four equal installments.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to RSU vesting and tax withholding. While there's a disposition of shares, it's for tax purposes, which is a neutral event. The acquisition of shares through vesting is generally positive as it increases insider ownership, even if a portion is sold for taxes. Overall, it's a neutral to slightly positive event reflecting standard compensation practices.

Positives

• CFO Frank Stokes acquired a total of 20,786 shares (14,616 + 6,170) through RSU vesting, indicating continued equity participation and alignment with shareholder interests.
• The transactions are routine for RSU vesting and tax withholding, reflecting standard executive compensation practices.

Negatives

• A total of 9,292 shares (6,534 + 2,758) were sold to cover tax obligations, which reduces the CFO's direct shareholding, though this is a common and expected practice.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically related to RSU vesting and tax-related sales. It does not provide insights into broader industry trends or competitive positioning for Castle Biosciences, which operates in the diagnostics and precision medicine sector.

Comparison to Industry Standards

• This filing details routine insider transactions related to equity compensation. Such transactions are standard practice across all industries for executives receiving Restricted Stock Units (RSUs) as part of their compensation package.
• The disposition of shares to cover tax obligations upon vesting is a common and expected event, not indicative of a specific company or industry performance trend.
• No specific comparable companies or projects are relevant for this type of routine disclosure.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in insider ownership due to equity compensation. The net effect on total shares outstanding is negligible, and the CFO's continued equity participation aligns interests with shareholders.
• Employees: The filing reflects standard executive compensation practices, which may be consistent with broader employee equity programs.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of Restricted Stock Units (RSUs) and the subsequent sale of shares to cover tax obligations. Such events are standard for executive compensation and do not provide new material information regarding the company's operational performance, financial health, or strategic outlook that would warrant a change in investment recommendation. The transactions are neutral in their implications for the stock's fundamental value.

Keywords

Castle Biosciences, CSTL, Form 4, Insider Transaction, Frank Stokes, CFO, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Beneficial Ownership